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Am J Physiol Heart Circ Physiol 295: H1414–H1421, 2008. First
published August 1, 2008; doi:10.1152/ajpheart.01219.2007.—Sev-
eral epidemiologic and clinical studies show that following myocar-
dial infarction, dietary supplements of -3 polyunsaturated fatty acids
(3FA) reduce sudden death. Animal data show that 3FA have
antiarrhythmic properties, but their mechanisms of action require
further elucidation. The effects of 3FA supplementation were stud-
ied in female rabbits to analyze whether their antiarrhythmic effects
are due to a reduction of triangulation, reverse use-dependence,
instability, and dispersion (TRIaD) of the cardiac action potential
(TRIaD as a measure of proarrhythmic effects). In Langendorff-
perfused hearts challenged by a selective rapidly activating delayed
rectifier potassium current inhibitor that has been shown to exhibit
proarrhythmic effects (dofetilide; 1 to 100 nM), 3FA pretreatment
(30 days; n  6) prolonged the plateau phase of the monophasic
action potential; did not slow the terminal fast repolarization; reduced
the dofetilide-induced prolongation of the action potential duration;
reduced dofetilide-induced triangulation; and reduced dofetilide-in-
duced reverse use-dependence, instability of repolarization, and dis-
persion. Dofetilide reduced excitability in 3FA-pretreated hearts but
not in control hearts. Whereas torsades de pointes (TdP) were ob-
served in five out of six in control hearts, none were observed in
3FA-pretreated hearts. Docosahexaenoic acid (DHA) inhibited the
sodium current with ultrafast kinetics. Dietary 3FA supplementation
markedly reduced dofetilide-induced TRIaD and abolished dofetilide-
induced TdP. Ultrafast sodium channel block by DHA may account
for the antiarrhythmic protection of the dietary supplements of 3FA
against dofetilide-induced proarrhythmia observed in this animal
model.
antiarrhythmia agents; omega-3 fatty acids; ion channels; torsades de
pointes
ORAL SUPPLEMENTATION WITH fish oils or ethyl esters of -3
polyunsaturated fatty acids (3FA) are associated in some
large clinical studies with significant risk reductions of sudden
cardiac death, which, although not directly compared in a
head-to-head trial, appear larger than those observed with
amiodarone in similar study populations, with less toxicities (1,
2, 9, 11, 14, 27). However, controversy exists about the pro- or
antiarrhythmic effects of 3FA (8, 35). Antiarrhythmic effects
of 3FA have been reported in animal (5, 33) and in cellular
models (29). Similar to amiodarone, it has been reported that
3FA block sodium (42), calcium (41), and potassium chan-
nels (17, 24, 26); likewise, they also exhibit antiadrenergic
actions (36). In contrast with amiodarone, at therapeutic con-
centrations, 3FA do not widen QRS or prolong the QT
interval (13). Many class III antiarrhythmic drugs such as
dofetilide, as well as noncardiac drugs, can be associated with
a prolongation of the QTc interval of the electrocardiogram
(ECG) and development of polymorphic ventricular arrhyth-
mias torsades de pointes (TdP), an arrhythmia where the ECG
exhibits characteristic twisting undulations of the cardiac acti-
vations. Therefore, QT prolongation itself is regarded by some
as a proarrhythmic liability (37). Changes of the QT interval on
the surface ECG generally reflect changes of the plateau and
the repolarization phase of the action potential but can also be
affected by changes in the conduction and dispersion of the
APD. It thus follows that the QT interval can be lengthened by
slowed repolarization and sometimes by slowed conduction
and dispersion of the action potentials as well. Slowed repo-
larization gives the action potential a more triangular shape,
referred to as triangulation (21). To be effective against tachy-
arrhythmias, drug-induced prolongation of action potential
duration (APD) should be most marked during tachycardia;
instead many drugs prolong the APD little during tachycardia,
but primarily at slow heart rates. This is termed reverse
use-dependence (21), which inherently leads to the instability
of APD (38). Finally, all three mechanisms result in spatial and
temporal dispersion. Triangulation, reverse use-dependence,
instability, and dispersion are referred to as TRIaD. APD
prolongation without TRIaD can be antiarrhythmic, whereas
drugs inducing TRIaD are proarrhythmic, inducing preferen-
tially TdP when APD is prolonged but ventricular fibrillation
when APD is shortened (20, 21, 38).
Therefore, in the present study we investigated the effects of
dietary supplements of esterified 3FA: 1) how do they block
sodium channels without widening the QRS, 2) what are their
effects upon TRIaD, 3) can they antagonize the proarrhythmic
effects of drugs that increase TRIaD (e.g., dofetilide), 4) by
what mechanism(s) might they be considered a powerful anti-
arrhythmic alternative, and 5) under what conditions might
they be less effective.
MATERIALS AND METHODS
The effects of 3FA feeding as used in the Gruppo Italiano per lo
Studio della Sopravvivenza nellInfarto miocardico (GISSI Prevenzi-
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one study) (14) were studied in 2.5-kg female rabbits. Rabbits were
selected because, as in humans, the main repolarizing current in the
ventricles is the rapidly activating delayed rectifier potassium current
(IKr). Females were selected because, as in humans, they appear more
sensitive to the development of TdP (30). Other species were deemed
less appropriate because the rat has the transient outward potassium
current (ITO) current as the primary repolarizing current, whereas dogs
and guinea pigs have much slow delayed rectifier potassium current
(IKs) in addition to IKr, which may obscure any proarrhythmia; dog
hearts are also too large for easy Langendorff perfusion. The
rabbits were fed with standard Lapina (Quartes, Belgium) at
libitum. Six hearts from animals fed with food enriched with 15 mg
3FA kg1 day1 for 30 days [mixing daily 55% eicosapentaenoic
acid ester (EPA-EE) and 45% docosahexaenoic acid ethyl ester
(DHA-EE) to their food as required; Omacor; Solvay] were compared
with six control hearts. The investigation conforms to the Guide for
Care and Use of Laboratory Animals published by the National
Institutes of Health (NIH Publication No. 85-23, Revised 1996) and
was approved by the Veterinary Department of the Belgian Govern-
ment. Following stunning by the captivating bolt, the heart was
quickly removed and perfused in the Langendorff mode.
The His-bundle was sectioned, and the distal part was stimulated.
Recording electrodes were placed under the left ventricular endocar-
dium and on the epicardium. A grounded potassium-perfused elec-
trode served as the reference. The heart was perfused at a constant
pressure of 80 cmH2O with a bicarbonate buffer containing (in mM)
118 NaCl, 4 KCl, 22 NaHCO3, 1.1 MgCl2, 0.4 NaH2PO4, 1.8 CaCl2,
5 dextrose, 2 pyruvate, and 0.038 creatine. The perfusate was equil-
ibrated with 95% O2-5% CO2 adjusted to obtain a pH of 7.35 at 36°
to 37°C. Stimulation occurred at 1.5 times the threshold stimulation
current. More detailed descriptions of the experimental system were
described previously (19).
Electrophysiological measurements. The experiment consisted of
brief and long protocols. The brief protocols were applied every
minute and consisted of a 30-s train at a cycle length of 1,000 ms,
followed by 10-s trains at cycle lengths of 750 and 300 ms. The long
protocols were executed after 15-min equilibration periods at each
concentration studied, 0, 1, 3, 10, 30, and 100 nM dofetilide, and
terminated with a 10-min washout period. These concentrations cover
the therapeutic range of 1–3 nM as well as proarrhythmic concentra-
tions (10–100 nM).
In the long protocols the following parameters were measured:
automaticity (nonstimulated spontaneous heart rate in beats per
minute) and escape cycle length (when stopping stimulation, the
number of milliseconds passing before a spontaneous beat results),
coronary perfusion rate (milliliters per minute), ectopic activity (beats
per minute), left ventricular septal and epicardial monophasic action
potential (MAP) duration (milliseconds) at 30% (APD30), 60%
(APD60), and 90% (APD90) of repolarization (APD30 and APD90 are
less accurate because repolarization may be very slow, so for quan-
titative comparisons we used APD60), activation time of the ventricles
(milliseconds), triangulation (APD90 to APD30), reverse use-depen-
dence, instability (beat-to-beat variability in APD), and dispersion of
repolarization (beat-to-beat variability between septal and epicardial
APD60). Conduction was measured as the duration of significant
levels of high-frequency activation following each stimulus (18).
Reverse use-dependence is measured as the difference in APD60
between the first 10 and subsequent 20 action potentials during a train
of 30 at 1 Hz. Threshold stimulation current (microamperes) is
determined as the minimum 2-ms current pulse that, at a cycle length
of 400 ms, results in the activation of the heart. When the maximum
available stimulation current of 1,000 A becomes unable to drive the
heart, the heart is then declared unexcitable. The effective refractory
period was determined by progressively delaying an extra pulse until
it is captured at 1 Hz (a walking-out pulse). The development and
number of early afterdepolarizations (EADs) and TdPs were detected
by an automated computer algorithm. The procedures are described in
more detail elsewhere (21, 22, 38). In addition, the instability of the
repolarization time (APD30 to APD90) was measured as a Poincare´
plot (PC30–90), where the repolarization time is plotted against that of
the preceding action potential. If all action potentials have similar
repolarization times, then a single point on the diagonal line results
(see Fig. 4C, left inset); as repolarization varies, deviations from the
diagonal increase (Fig. 4C, right inset). The sum of the distance to the
diagonal was computed at each concentration for 450 action poten-
tials.
A fresh stock solution of 100 M dofetilide in dimethylsulfoxide
(DMSO) was made daily and pumped into the bubble trap under
computer control at the rate required to achieve the desired dofetilide
concentrations. The DMSO concentration remained 0.1% at all
times.
Sodium current measurements. Human embryonic kidney (HEK)293
cells that do not express endogenously sodium channels or accessory
subunits were cultured at 37°C in DMEM supplemented with peni-
cillin-streptomycin (Sigma, London, UK), 10% bovine fetal serum,
and 1% nonessential amino acids in a 5% CO2 atmosphere (15).
Transfection of Nav1.5 channels (2 g) and CD8 (1 g) was per-
formed using Lipofectamine2000 (10 l). Before experimental use,
the cells were incubated with polystyrene microbeads precoated with
anti-CD8 antibody (Dynabeads M450; Dynal Biotech, Oslo, Norway)
as described (15).
The intracellular pipette filling solution contained (in mM) 5 NaCl,
5 KCl, 130 CsF, 1 MgCl2, 4 Na2ATP, 10 HEPES-K, and 5 EGTA and
was adjusted to pH 7.2 with CsOH. The bath solution contained (in
mM) 140 NaCl, 5 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES-Na, 10
glucose, 10 tetraethylammonium, and 2.8 Na-acetate and was adjusted
to pH 7.4 with NaOH. DHA (Sigma, St. Louis, MO) was dissolved as
previously described (17). Sodium currents were recorded at room
temperature (21–23°C) using the whole cell patch-clamp technique
with an Axopatch 1C patch-clamp amplifier (Axon Instruments,
Foster City, CA). Micropipettes were pulled from borosilicate glass
capillary tubes (GD-1; Narishige, Tokyo, Japan) on a programmable
horizontal puller (P-87; Sutter Instrument, San Rafael, CA) and heat
polished with a microforge (Narishige). To minimize voltage errors,
micropipette resistance was 1 to 2 M. Data analysis was performed
using the CLAMPfit program of pCLAMP 9.0.1 and Origin 7.0.3
(Microcal Software, Northampton, MA). The curve-fitting procedure
used a nonlinear least-squares (Gauss-Newton) algorithm; results
were displayed in linear and semilogarithmic format, together with the
difference plot.
Free 3FA are generally toxic to cells and are kept at low
micromolar concentrations in plasma. However, the plasma-free
3FA concentration can vary greatly depending on the hormonal,
metabolic, and nutritional state of the individual. About 99.9% of free
3FA are bound to albumin in the plasma (10). The low plasma
concentration of free 3FA is maintained by a competition between
binding sites on albumin and cell membrane phospholipids. The range
of free DHA human plasma concentration is 2.8 M (10). Since
DHA and EPA can compete each other for binding to Nav1.5
channels, we chose to analyze only the effects produced by DHA on
the current generated by their activation.
Statistical analysis. Data are expressed as means  SE. Compar-
isons of two means were done using a Student’s t-test, and P  0.05
was considered significant. Instability and unexcitability were not
normally distributed so that nonparametric tests were used instead.
Goodness of fit was judged by the 	2 criterion (17). Comparison of
events was done with a Fisher exact test. Due to the small number of
experiments (n  6) and large variation of effects, only major drug
effects can become significant.
RESULTS
Effects of dietary supplements of 3FA. 3FA significantly
prolonged APD30, APD60, and APD90 (Table 1). APD30 was
H1415ANTIARRHYTHMIC EFFECTS OF FISH OIL
AJP-Heart Circ Physiol • VOL 295 • OCTOBER 2008 • www.ajpheart.org
prolonged more than APD90 (Fig. 1), i.e., 3FA prolonged the
APD without triangulation. As expected, the prolongation of
APD resulted in a significant prolongation of the effective
refractory period (ERP), but this prolongation was more than
twice as long as the prolongation of APD90 (Table 1). Thus
additional electrophysiological change(s) must play an impor-
tant role (discussed in Dofetilide leads to unexcitability in
3FA-pretreated hearts).
At baseline (i.e., before the administration of dofetilide),
3FA pretreatment had no significant effects on reverse use-
dependence, instability, dispersion, or ectopic activity, and
neither group exhibited TdP or ventricular tachycardia (VT).
Threshold stimulation current and activation times were also
not significantly changed (Table 1).
Dofetilide leads to unexcitability in 3FA-pretreated hearts.
All control hearts could fully execute the experiment (includ-
ing 100 nM dofetilide), whereas none of the 3FA hearts
could; one heart became unexcitable at 10 nM dofetilide, and
all others at 30 nM [no data at 100 nM in 3FA-pretreated
hearts (Fig. 2, right)].
Since dofetilide acts by a class III mechanism (40), pretreat-
ment with 3FA might emphasize the prolongation of the
action potential of dofetilide and thereby lead to unexcitability.
However, 10 nM dofetilide prolonged APD90 by 235  75 ms
in control but only by 193 47 ms in 3FA hearts (P 0.64);
30 nM dofetilide prolonged APD90 by 402 152 ms in control
but only by 247  107 ms in 3FA hearts (P  0.47).
Furthermore, APD60 started to exceed 1,000 ms at 3 nM
dofetilide in control hearts (Fig. 2) but only at 30 nM dofetilide
in 3FA-pretreated hearts. In control hearts there were 467
APD60 measurements exceeding 1,000 ms but only six in
3FA hearts, whereas 26 APD60 measurements exceeded
1,500 ms in control hearts, and no such prolongations occurred
in 3FA hearts. Finally, APD60 
1,000 ms occurred in four
control hearts but was seen in only one 3FA experiment.
Thus 3FA pretreatment clearly does not augment dofetilide-
induced APD prolongation and cannot account for the unex-
citability in 3FA-pretreated hearts.
A block of sodium channels can also reduce excitability (34,
43). However, in control hearts dofetilide did not slow con-
duction, agreeing with reports that dofetilide does not block
sodium channels. In control hearts, conduction slowed indi-
rectly when the action potential impinged on the tail of the
preceding action potential. However, in all 3FA experiments,
the slowing of conduction was already noted at short diastolic
intervals, i.e., before impinging on the tail of the preceding
action potential. In fact, no conduction was possible until 30
ms following the end of the preceding action potential. Inter-
estingly, action potentials triggered about 60 ms after the end
of the action potential conducted at virtually normal velocity.
Thus if this extension of refractoriness was due to block of
sodium channels, then there had to be a marked block at short
diastolic intervals but virtually no block at slightly longer
intervals. Attempts to characterize such fast recovery appeared
impossible with the MAP; the time interval over which the
recovery occurred was so brief that only rarely could an
intermediate conduction velocity be observed. Furthermore, in
the presence of dofetilide, the variability of APD rendered it
nearly impossible to hit this brief time period. Therefore, the
effects of DHA on sodium current were studied with voltage
clamp to be able to analyze this recovery process in a short
period of time.
DHA (1 M) reduced the sodium current only slightly when
membrane potential was maintained (holding potential) at
120 mV (Fig. 3A). However, at 90 mV, it decreased
significantly and at 80 mV the block became 42.0  7.1%
(n 6; P 0.05). The block increased sharply with increasing
concentrations so that by 10 M, the marked reduction of the
current already developed even at 120 mV. Since we were
primarily interested in therapeutic concentrations that do not
reduce the current at well-polarized potentials (120 mV),
the kinetic studies were therefore done at 1 M.
Following a 500-ms depolarizing pulse, a 10-ms test pulse
was applied after various recovery times and at different
holding potentials (Fig. 3B, inset). The Nav1.5 magnitude of
the current recorded in the test pulse was plotted versus the
time elapsed between the end of the 500-ms prepulse and the
beginning of the test pulse. From these data, the recovery time
constant (re) for the sodium currents was extracted by least-
square fitting of the data. At 120 mV, re was 9.4  2.3 ms
and similar to that observed in control cells (9.4  2.0 ms; n 
Fig. 1. Comparison of the mean action potential of control (gray) vs. -3
polyunsaturated fatty acids (3FA)-pretreated (black) animals. In the 3FA-
pretreated animals, the plateau phase of the monophasic action potential is
flatter and requires more time before the fast, final repolarization begins.
APD30, APD60, and APD90, action potential duration at 30%, 60%, and 90%,
respectively.
Table 1. Comparison of electrophysiological characteristics
obtained in control and 3FA-pretreated rabbit hearts
Group
P ValueControl 3FAs
Action potential duration, ms
At 30% 1653.2 20415.0 0.02
At 60% 2175.5 24810.7 0.02
At 90% 2526.2 27812.4 0.02
Effective refractory period, ms 21622.9 2784.9 0.01
Reverse use-dependence, ms 20.8 30.9 
0.05
Instability, ms 50.9 40.7 
0.05
Dispersion, ms 195.4 175.0 
0.05
Ectopics per minute 0.50.13 0.40.15 
0.05
Threshold stimulation current, A 14641 16937 
0.05
Activation time, ms 492.0 513.2 
0.05
Values are means  SE; n  6/group. P, comparison between parameters
from -3 polyunsaturated fatty acids (3FA)-pretreated and control rabbits.
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5; P 
 0.05). However, as the holding potential became less
negative, re markedly prolonged; by 90 mV, re increased
from 25.2  5.0 ms in control to 49.0  7.3 ms in 1 M DHA
(n  6; P  0.01). Thus recovery kinetics of Nav1.5 channels
in the presence of 3FA is an ultrafast process, i.e., not much
slower than in control.
Thus block induced by 1 M DHA was measured at the
maximum peak of a 10-ms test pulse to10 mV from different
holding potentials applied after a 10- or a 500-ms prepulse. The
degree of block measured at the test pulse after the 10- or
500-ms prepulse from the four different holding potentials
(120, 100, 90, and 80 mV) was similar: 12.0  5.2%
vs. 30.3  9.7% at 120 mV (n  6; P 
 0.05), 16.8  5.6%
vs. 34.1 8.9% at100 mV (n 6; P
 0.05), 18.9 4.8% vs.
35.8 7.2% at90 mV (n 5; P
 0.05), and 42.0 7.1% vs.
35.4  5.2% at 80 mV (n  4; P 
 0.05). Thus, upon
depolarization, sodium channels quickly become blocked;
there is marked block in less than 10 ms, and after only 500 ms
most of the channels become blocked. Once the membrane
potential becomes sufficiently negative, recovery occurs ultra-
fast; even at 25°C, re becomes shorter than 50 ms.
3FA pretreatment prevents dofetilide-induced TdP. In con-
trol hearts, dofetilide induced TdP in five of the six hearts but
in none following 3FA pretreatment. Since the primary cause
for TdP is TRIaD (21, 38), we characterized the effects of
3FA pretreatment upon these four parameters.
Triangulation increased with the dofetilide concentration
(Fig. 4B), but in both groups starting at 10 nM it exceeded the
upper 97.5% confidence limit of 29 ms previously determined
in normal rabbit hearts (23). At 30 nM dofetilide, triangulation
reached 222  109 ms in control hearts, but it also increased
to 91  55 ms (P  0.29; vs. control hearts) in 3FA-
pretreated hearts.
Reverse use-dependence increased significantly starting
from 10 nM and exceeded the upper 97.5% confidence limit of
6 ms in both groups (Fig. 4A) (23). However, in control hearts,
at 10 nM dofetilide, reverse use-dependence increased to 32 
11 ms and only to 8  6 ms in 3FA (P  0.025; vs. control
hearts). At 30 nM dofetilide, reverse use-dependence reached
47  24 ms in control hearts but was only 1  25 ms in
3FA-pretreated hearts.
Instability increased to 943  485 ms in control hearts and
to 344  156 ms in 3FA-pretreated hearts by 10 nM dofeti-
lide (Fig. 4C). Both values exceeded the proarrhythmic upper
97.5% confidence limit of 136 ms previously determined in
normal rabbit hearts (23). At 30 nM, instability further in-
creased to reach 3,208  2,013 ms in control hearts and 498 
201 ms in 3FA-pretreated hearts (P  0.037; vs. control
hearts).
Spatial and temporal dispersion of APD60 increased in
control hearts and 3FA (Fig. 4D). At 10 nM it was 60  12
ms in control hearts and 41  18 ms in 3FA-pretreated
hearts, both values exceeding the proarrhythmic upper 97.5%
confidence interval of 23 ms, previously determined in normal
rabbit hearts (23). At 30 nM, dispersion further increased to
Fig. 2. Comparison of the dofetilide-induced prolongation of APD60 in control and 3FA-pretreated hearts. Every minute the hearts were stimulated for 30 s
at a cycle length of 1,000 ms, and their APD60 is plotted as a function of time into the experiment. The first group of data points (0 to 1,700 ms) represents the
drug-free period. This is followed by 1 nM (1,700 to 3,300 ms), 3 nM (3,300 to 4,900 ms), 10 nM (4,900 to 6,400 ms), 30 nM (6,400 to 8,100 ms), and finally
100 nM (8,100 to 9,000 ms) dofetilide. In the 3FA-pretreated group, 1 heart became unexcitable during perfusion with 10 nM dofetilide, and all others during
30 nM, so that, at right, no data points could be measured at 100 nM. The 97.5% confidence interval for APD prolongation in control hearts is shown as a solid
horizontal line.
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reach 89  24 ms in control hearts and 49  5 ms in
3FA-pretreated hearts (P  0.13).
Proarrhythmia. Stalling of repolarization rate (repolariza-
tion rate  0) (38) started at 1 nM in two of six control hearts,
but stalling required 10 nM in 3FA hearts, where it then
developed in three of six hearts. EADs began at 3 nM in
control hearts and at 10 nM in 3FA. Finally, TdP and VT
started to develop at 3 nM dofetilide in control hearts; more-
over, dofetilide induced TdP in five out of six control hearts. In
contrast with that of the 3FA-pretreated hearts, there was a
Fig. 3. 3FA effects on sodium current. A: effects of docosahexaenoic acid (DHA; 1 and 10 M) on Nav1.5 current measured after applying 10-ms depolarizing
pulses from different levels of holding potentials (between 120 mV and 80 mV). B: a double-pulse protocol consisting in a 500-ms prepulse to 10 mV
followed by a 10-ms test pulse to the same level from different holding potentials (120, 100, and 90 mV) after different recovery time periods. DHA
(1 M) only slowed the recovery process when it was analyzed from a holding potential positive to 100 mV. re, recovery time constant; Vh, half-maximal
voltage. *P  0.05, changes are significant.
Fig. 4. Comparison of the dofetilide triangulation, reverse
use-dependence, instability, and dispersion in control
(solid line) and in 3FA-pretreated animals (dotted line)
with upper 97.5% confidence interval limit for normal
rabbit hearts (dotted line with tick on y-axis). Different
concentrations of dofetilide (x-axis; nM) tested for trian-
gulation (A), reverse use-dependence (B), instability (C),
and dispersion (D). C, inset: a Poincare´ plot in drug-free
heart (left) with a Poincare´ plot in 10 nM dofetilide (right).
Axes of the inset panels are 400 ms (experiment, 16,434).
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single heart that exhibited VT at 10 and 30 nM dofetilide; most
importantly, not a single TdP was observed in the six 3FA
hearts (Fisher exact test; P  0.01).
DISCUSSION
Our results demonstrate that 3FA pretreatment completely
suppresses dofetilide-induced TdP (which occurred in 5 out of
6 control hearts), does not induce TRIaD, and attenuates
dofetilide-induced TRIaD and that DHA (in acute treatments)
blocks sodium channels with ultrafast kinetics.
The pharmacological profile of 3FA strikingly matches
that of amiodarone: block of sodium, potassium, and calcium
channels as well as - and -adrenoceptors (17, 24, 26, 41, 42).
Most importantly, the cardioprotective effects of 3FA ob-
served in the GISSI Prevenzione study (14) were better than
those previously reported with amiodarone (27). Our present
observations may account for some of these advantages;
whereas amiodarone has been found to induce some triangu-
lation (38), 3FA do not. Although amiodarone also has fast
kinetics of recovery from sodium channel block (32), its onset
and offset kinetics are still nearly one order of magnitude
slower than those of 3FA reported in the present study (38).
Since clinical use of amiodarone is hampered by its many
toxicities (16), the adverse side effects of 3FA are limited to
weak inflammatory and hemostasis disorders (28). Therefore, it
could be speculated that 3FA could be a highly effective and
nontoxic adjunct to other strategies for the prevention of
myocardial ischemia-related sudden death. However, contrary
to reports of the beneficial effects of 3FA consumption or
supplements on cardiac deaths in some populations (14), other
trials have suggested a neutral effect in patients with implanted
cardioverter defibrillators (7, 35) and even a deleterious effect
in men with angina (8). It is unclear whether these contradic-
tory observations on the effects of 3FA supplementation can
be accounted for by different population characteristics (e.g.,
angina vs. post-myocardial infarction or heart failure), possible
toxic effects of mercury exposure associated with fish intake,
background fish consumption in the control population, or the
type of arrhythmogenic mechanism (e.g., triggered activity vs.
reentry arrhythmias) (12).
The ultrafast onset and recovery kinetics of DHA sodium
channel block, never observed before with other agents (30
ms), ensures that conduction is not slowed, except for a brief
window early in diastole. Since the recovery of the sodium
currents is not much slower than normal, the vulnerable period
would not be widened much, as is seen with other sodium
channel blockers (34); instead, it would only be delayed. At
25°C and at 90 mV, the  for recovery from sodium channel
block is about 50 ms. As the membrane potential is made more
negative, recovery becomes increasingly faster, until at 120
mV, recovery closely tracks the reactivation of control sodium
channels (Fig. 3B). If this time constant were to exhibit a
similar temperature dependence as is the case with other
sodium channel blockers (25), then at 37°C recovery of block
could easily be three times faster. Furthermore, these recovery
characteristics would also be shifted by about 20 mV to more
positive potentials (25). Such fast kinetics would well explain
our observations that, except for a brief early diastolic window,
conduction would not be slowed. However, during and before
this early diastolic window, sodium channels would not be
available. Hence throughout the cardiac action potential and
specifically during the rapid repolarization period, no inward
sodium current activation would be available. Therefore, upon
reaching a normal resting potential, recovery would be com-
plete in a time frame similar to that of reactivation in control.
Thus the period of slowed conduction (partial availability of
sodium channels) would be little or not prolonged, i.e., just
delayed.
This profile of sodium channel block has three important
clinical consequences. First, whereas in well-polarized tissue
sodium channels would behave normally, except for a small
delay of their availability, in ischemic tissue recovery would be
very slow or may not occur at all. As a result, tissue depolar-
ized by an ischemic event (responsible for proarrhythmia)
would remain unavailable for participation in reentry. This
mechanism could contribute to the clinical observation that
3FA reduce sudden death upon reinfarction (14) but might
not protect against ventricular arrhythmia in the absence of
ischemia (7). Second, much evidence has accumulated that
blockers of IKr are less torsadogenic provided they also block
inward currents (sodium and/or calcium) at lower concentra-
tions than those needed to block IKr (6, 23). Our results on the
effects of 3FA on sodium channels, together with those
previously reported on L-type Ca2 channels (41), may ac-
count for the complete suppression of dofetilide-induced TdP
in 3FA-pretreated hearts observed in the present study. Fi-
nally, it may be of interest to test in a clinical trial whether the
danger of sudden death is reduced by 3FA feeding in specific
clinical diseases such as congenital long-QT syndrome type 2,
characterized by human ether-a-go-go-related gene (HERG)
channel dysfunction.
Dofetilide-induced TRIaD was attenuated by pretreatment
with dietary supplements of 3FA. Although these reductions
of TRIaD were not large enough to stay within safe limits (21,
23, 38), nevertheless these simultaneous reductions may also
have contributed to the observed reduction of dofetilide-in-
duced TdP. However, the fact that TRIaD could not be com-
pletely suppressed, whereas TdP was entirely prevented, fur-
ther supports that the block of sodium channels with ultrafast
kinetics potentially plays a key role. If so, then 3FA might
reduce the rare occurrences of TdP and render cardiac as well
as noncardiac agents with such liability safer to use.
The effects of 3FA on the APD and, thus, indirectly on the
repolarizing currents observed in this chronic rabbit model are
at variance with findings in other animal species (39) in
different experimental conditions using isolated cells (39) or
-linolenic acid (4) and after acute administration at different
concentrations of 3FA (31). The rabbit animal model differs
from other species in that the repolarization phase of the APD
is exclusively dependent upon IKr, and that could explain in
part the differences observed between species. In contrast,
block of sodium currents by 3FA is consistently observed in
all species.
Limitations of the present study. The present paper has
several experimental limitations: 1) the effects of 3FA on
sodium channels were analyzed by studying the effects of
DHA (not DHA  EPA) on Nav1.5 channels transiently
expressed in HEK293 cells; 2) no voltage-clamp studies on
myocytes obtained from 3FA-fed rabbits were done; 3) the
beneficial effects of 3FA were demonstrated after 30 days of
pretreatment, so the time course of development of this benefit
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is unknown; and 4) specifically, our study cannot rule out that
the benefits might not be preceded by untoward effects (which
could help account for some of the clinical inconsistencies).
The fast sodium channel block with fast kinetics holds for
chronic exposure, but preliminary experiments suggest that
these effects are more difficult to establish in acute experiments
(unpublished observations). Thus additional studies will be
needed to address these limitations.
Conclusions
The cardiac effects of 3FA resemble those of amiodarone;
both block sodium, calcium, and potassium channels, have
antiadrenergic properties, and can prolong the APD, reverse
TRIaD, and suppress TdP. The main difference is that sodium
channel block by 3FA has a much faster onset and offset
kinetics. As a result, the electrophysiological profile of 3FA
appears more desirable; the duration of reduced sodium current
(facilitates reentry) is much shorter. These properties, together
with the safer profile of 3FA versus other antiarrhythmic
agents, may account for the clinical observation that risk
reduction of sudden cardiac death with dietary supplementation
of 3FA, although not directly compared in a head-to-head
trial, appears larger than with amiodarone in post-myocardial
infarction patients (3, 14, 27). Moreover, if further research
confirms that 3FA or some components of 3FA may sup-
press drug-induced TdP, they could be used to salvage certain
valuable medications that would otherwise be rejected for
medical use. Finally, it would be interesting to investigate the
efficacy of the dietary supplementation of 3FA to reduce
the arrhythmic dangers of certain clinical disease states such
as the congenital long-QT syndrome type 2, characterized
by HERG channel dysfunction.
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